Association of C3435T (rs1045642) polymorphism of the MDR1 gene with the increased risk of colorectal cancer in russian females from Central Russia by Moskalev, A. S. et al.
1514
ISSN 1022-7954, Russian Journal of Genetics, 2019, Vol. 55, No. 12, pp. 1514–1519. © Pleiades Publishing, Inc., 2019.
Russian Text © The Author(s), 2019, published in Genetika, 2019, Vol. 55, No. 12, pp. 1417–1423.
Association of C3435T (rs1045642) Polymorphism
of the MDR1 Gene with the Increased Risk of Colorectal
Cancer in Russian Females from Central Russia
A. S. Moskaleva, b, E. M. Baryshevac, V. O. Soldatovc, d, O. G. Frolovae, O. V. Bobyntsevaa, c,
T. A. Samginaf, M. I. Churnosovg, V. P. Ivanovc, A. V. Polonikova, c, and O. Yu. Bushuevaa, c, *
aResearch Institute of Genetic and Molecular Epidemiology, Kursk State Medical University, Kursk, 305004 Russia
bKursk Regional Clinical Oncology Dispensary, Kursk oblast, farmstead of Kislino, 305524 Russia
cDepartment of Biology, Medical Genetics, and Ecology, Kursk State Medical University, Kursk, 305004 Russia
dDepartment of Pharmacology and Clinical Pharmacology, Belgorod National Research University, Belgorod, 308015 Russia
eDepartment of Oncology, Kursk State Medical University, Kursk, 305004 Russia
fDepartment of Surgical Diseases No. 2, Kursk State Medical University, Kursk, 305004 Russia
gDepartment of Biomedical Disciplines, Belgorod National Research University, Belgorod, 308015 Russia
*e-mail: olga.bushueva@inbox.ru
Received January 12, 2019; revised March 12, 2019; accepted April 9, 2019
Abstract—The objective of this study was to examine associations of single nucleotide polymorphisms,
rs1045642 within the MDR1 gene and rs1799930 within the NAT2 gene, with the risk of colorectal cancer
(CRC) in the population of Central Russia. DNA specimens were obtained from 178 patients with CRC
(87 males and 91 females) and 327 age-matched healthy controls (179 males and 148 females). Genotyping
was performed using real-time PCR. Association of the studied SNPs with the risk of CRC was evaluated
using logistic regression analysis. It was demonstrated that MDR1 rs1045642 polymorphism was associated
with the increased risk of CRC after correction for gender, age, and smoking (OR = 1.41, 95% CI = 1.09–
1.83; P = 0.008). A gender-stratified analysis showed that MDR1 rs1045642 was associated with the increased
risk of CRC only in females (OR = 1.62, 95% CI = 1.11–2.35; P = 0.01). In males, no association between
MDR1 rs1045642 and CRC was found. Association between MDR1 rs1045642 and the increased risk of col-
orectal cancer in Russian females from Central Russia was revealed.
Keywords: colorectal cancer, hereditary predisposition, MDR1, NAT2, rs1045642, rs1799930
DOI: 10.1134/S1022795419120093
INTRODUCTION
Colorectal cancer (CRC), including colon and rec-
tal cancer, is one of the most common cancers world-
wide [1]. Previous epidemiological studies have shown
that genetic susceptibility factors together with envi-
ronmental factors (such as smoking, nutrition, bacte-
rial toxins, etc.) can increase the risk of CRC [2].
However, the exact mechanisms underlying the devel-
opment of this malignant tumor of the digestive sys-
tem remain unclear.
Arylamine N-acetyltransferase 2 (NAT2) is an
enzyme involved in the Phase II of xenobiotic bio-
transformation. It catalyzes the metabolism of envi-
ronmental carcinogens (aromatic hydrocarbons, het-
erocyclic amines, and hydrazines), as well as some
polar compounds (such as methyl and acetyl) [3].
NAT2 is most highly expressed in the liver and intesti-
nal mucosa. The gene encoding NAT2 is polymor-
phic. The G > A substitution at the position 590 of
NAT2 (rs1799930) determines the acetylator pheno-
type, which is subdivided into rapid and slow ones.
The acetylator status, in turn, can affect the metabo-
lism of certain carcinogens, the activation/inactiva-
tion of which may be at risk of CRC. Analyses of asso-
ciations between the NAT2 acetylator phenotypes and
CRC showed conflicting results. For instance, Probst-
Hensch et al. [4] found an inverse correlation between
the NAT2 rapid acetylator genotype and colorectal
adenoma in black Americans; however, in white
Americans, this genotype was associated with the
increased risk of this disease. Other studies have also
shown that the rapid NAT2 genotype played an
important role in susceptibility to colorectal cancer
[5]. At the same time, previous meta-analysis showed
a lack of association between NAT2 rs1799930 and
CRC [6].
The multidrug resistance 1 gene (MDR1, also
called the ATP-binding cassette transporter, subfamily
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B, member 1 (ABCB1)) encodes transmembrane gly-
coprotein, P-glycoprotein (P-gp), participating in the
Phase III of xenobiotic biotransformation [7].
C3435T (rs1045642), one of the most studied SNPs in
the MDR1 gene, affects the P-gp functional properties
[8]. In 2005, Kurzawski et al. [9] were analyzed, for the
first time, an association between MDR1 C3435T and
the development of CRC in the Polish population. It
was demonstrated that MDR1 3435TT genotype was
associated with a 2.7-fold higher risk of colon cancer.
Then, the number of studies on the association of this
polymorphism with the development of CRC
increased considerably with most of them performed
on Asian populations. However, the results were con-
tradictory [10–12]. For instance, Komoto C. et al. [11]
revealed the effect of MDR1 rs1045642 on the devel-
opment of CRC in the Japanese population [11].
At the same time, in two other studies performed in
Korea, no associations between rs1045642 MDR1 and
CRC were found [10, 12]. These contradictions can be
explaned by the small sample sizes of the studied
cohorts and low statistical power of the studies.
A recent meta-analysis showed a lack of association
between MDR1 C3435T and the risk of colorectal can-
cer in Europeans [13]. Another recent meta-analysis
showed the association between MDR1 C3435T poly-
morphism and a decreased risk of CRC in Asians [14].
Associations between NAT2 rs1799930 and MDR1
rs1045642 polymorphisms and the risk of colorectal
cancer in the population of Central Russia were not
studed yet.
The objective of this study was to analyze the asso-
ciations between NAT2 rs1799930 and MDR1
rs1045642 polymorphisms and the risk of colorectal
cancer in the population from Central Russia.
MATERIALS AND METHODS
A total of 505 unrelated Russian individuals from
Kursk region was examined; written informed consent
was obtained from all participants prior to entering the
study. The study included 178 CRC patients (87 males
and 91 females) who underwent inpatient treatment at
the Kursk Regional Clinical Oncology Center
between 2013 and 2017 [15]. The control group con-
sisted of 327 healthy volunteers (179 males and 148
females) without a history of chronic diseases. Patients
were included in the study group only after verification
of final diagnosis of the disease, confirmed by clinical,
laboratory and instrumental methods. The study was
approved by the Regional Ethics Committee of Kursk
State Medical University.
The mean age of CRC patients was 66.92 ± 9.27
years; the mean age of the control group individuals
was slightly higher – 68.71 ± 8.44 years (P = 0.02).
The groups (CRC patients and controls) were fre-
quency-matched according to gender (P > 0.05).
Venous blood samples were obtained from all individ-
1
2
uals. Genomic DNA was isolated from peripheral
blood by the standard phenol-chloroform extraction
method. Genotyping of NAT2 rs1799930 and MDR1
rs1045642 polymorphisms was performed by real-
time PCR using allelic discrimination assay with
TaqMan probes on a CFX96 amplifier (Bio-Rad,
USA). Regenotyping of 10% of the studied samples
taken randomly and in the absence of information on
the status of the disease showed 100% reproducibility
of the original results.
Associations of alleles with the risk of CRC were
performed using logistic regression analysis. To assess
association of genotypes with the disease, the odds ratio
(OR) and 95% confidence interval (CI) values calculated
for the log-additive regression model were used. All cal-
culations were performed adjusted for gender, age, and
smoking in the SNPStats software program, available
online (https://www.snpstats.net/start.htm). A value
of P ≤ 0.05 was taken as statistically significant.
RESULTS AND DISCUSSION
The genotype frequency distributions of the stud-
ied SNPs in the patient and control groups were in
Hardy–Weinberg equilibrium (P > 0.05). We were
unable to genotype MDR1 rs1045642 polymorphism
in one DNA specimen from the CRC patient group, as
well as in one DNA specimen from the control group.
The results of the analysis of associations of the stud-
ied polymorphisms with SRS risk are presented in
Table 1. According to the results, NAT2 rs1799930 was
not associated with the risk of colorectal cancer; at the
same time, MDR1 rs1045642 was associated with the
risk of CRC even after adjustment for gender, age, and
smoking habit (Table 1).
Taking into consideration the sexual dimorphism
of associations of the genetic markers with multifacto-
rial diseases, at the next step we performed gender-
stratified analysis of rs1045642 in the MDR1 gene
with the risk of colorectal cancer. In males, no associ-
ations between MDR1 rs1045642 and the risk of CRC
were detected. At the same time, in females, MDR1
rs1045642 polymorphism was associated with the risk
of CRC, taking into account adjustment for gender,
age, and smoking habit (Table 2).
A number of studies accumulated over the last
years provide evidence on the important role of
genetic factors in the pathogenesis of CRC [9–11].
The MDR1 gene, which encodes the ATP-binding
cassette transporter, P-gp, is mapped to chromosomal
region 7q21.12. It contains 29 exons and encodes a
protein containing 1280 amino acids [7]. To date,
more than 50 single nucleotide polymorphisms have
been identified in the MDR1 gene. A recent study
showed that synonymous substitution (C3435T) was
one of the most functionally important polymor-
phisms in the MDR1 gene, which changed the confor-
mation of the encoded P-gp and affected the timing of
1516
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cotranslational folding and introduction of P-gp into
the membrane, thereby changing the structure of sub-
strate and inhibitor interaction sites [8]. In addition,
Hoffmeyer et al. [16] showed a considerable decrease
in the level of MDR1 protein in duodenal tissues of
homozygous 3435TT carriers. Thus, rs1045642 poly-
morphism affects both the MDR1 gene expression and
P-glycoprotein activity.
Table 1. Analysis of associations of NAT2 rs1799930 and MDR1 rs1045642 with the risk of colorectal cancer
1P value with adjustment for gender, age, and smoking habit. 2 Odds ratio and 95% confidence interval. 3 Akaike information criterion.
* Statistically significant differences between groups are demonstrated. ! Indices calculated for the log-additive regression model with
adjustment for gender, age, and smoking habit.
Analysis of associations of NAT2 rs1799930 with the risk of CRC, combined groups
Minor allele/genotypes Patients(N = 178) Control (N = 327) P
1 OR
(95% CI)2
Minor allele frequency A 0.272 0.291 0.59 0.92(0.69–1.22)
Genotype frequencies,
N (%)
GG 93 (52.2%) 167 (51.1%)
0.63 0.93(0.70–1.24)GA 73 (41%) 130 (39.8%)
AA 12 (6.7%) 30 (9.2%)
Analysis of associations of MDR1 rs1045642 with the risk of CRC, combined groups
Minor allele/genotypes Patients(N = 177) Control (N = 326) P
1 OR
(95% CI)2
Minor allele frequency T 0.531 0.440 0.01* 1.44
(1.11–1.87)
Genotype frequencies,
N (%)
CC 41 (23.2%) 106 (32.5%)
0.008*!
1.41!
(1.09–1.83)!
CT 84 (47.5%) 153 (46.9%)
TT 52 (29.4%) 67 (20.6%)
Table 2. The influence of gender on associations of MDR1 rs1045642 with the risk of colorectal cancer
1 P value with adjustment for gender, age, and smoking habit. 2 Odds ratio and 95% confidence interval. 3 Akaike information criterion. * Sta-
tistically significant differences between groups are demonstrated. ! Indices calculated for the log-additive regression model with adjust-
ment for gender, age, and smoking habit.
Analysis of associations of MDR1 rs1045642 with the risk of CRC, males
Minor allele/genotypes Patients(N = 86)
Control
(N = 180) P
1 OR
(95% CI)2
Minor allele frequency T 0.500 0.444 0.27 1.25(0.87–1.80)
Genotype frequencies,
N (%)
CC 20 (23.3%) 58 (32.2%)
0.23
1.25
(0.87–1.79)CT 46 (53.5%) 84 (46.7%)
TT 20 (23.3%) 38 (21.1%)
Analysis of associations of MDR1 rs1045642 with the risk of CRC, females
Minor allele/genotypes Patients(N = 91)
Control
(N = 146) P
1 OR
(95% CI)2
Minor allele frequency T 0.560 0.435 0.01* 1.65
(1.14–2.40)
Genotype frequencies,
N (%)
CC 21 (23.1%) 48 (32.9%)
0.01*!
1.62!
(1.11–2.35)!
CT 38 (41.8%) 69 (47.3%)
TT 32 (35.2%) 29 (19.9%)
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Data on association of MDR1 C3435T with the risk
of CRC are contradictory. In some studies, a pro-
nounced association between MDR1 C3435T and sus-
ceptibility to CRC was demonstrated [17, 18]. In other
studies, association was not confirmed [10–12, 19]. To
study the association of the MDR1 gene with the risk
of CRC, a number of meta-analyses were performed.
For example, according to the results of a meta-analy-
sis which included ten studies of European popula-
tions, no association between MDR1 C3435T poly-
morphism and colorectal cancer was detected [13].
However, He T. et al. [20] showed that combined hap-
lotypes of several MDR1 SNPs, including rs1045642,
could be a reliable marker to determine the suscepti-
bility to CRC in Europeans, while MDR1 rs1045642
polymorphism was highly associated with the risk of
CRC in Asians. Another large meta-analysis based on
39 studies of different forms of cancer showed that car-
riage of the MDR1 3435TT genotype was associated
with an increased risk of different forms of cancer in
European populations [21].
It is known that the relative contribution of genetic
markers to susceptibility to CRC may vary depending
on the ethnic group. Moreover, a recent study showed
a considerable difference in the prevalence of the
MDR1 3435TT genotype among healthy Asians
(27.8%) and Europeans (49.4%) [22]. Thus, the rela-
tive contribution of MDR1 C3435T polymorphism to
the development of CRC may vary in different popu-
lations, and the role of MDR1 rs1045642 in colon car-
cinogenesis remains unclear.
The present study involved 178 CRC patients and
327 individuals from the control group. This is the first
study of association between MDR1 C3435T polymor-
phism and susceptibility to CRC in the Russian popu-
lation. The data obtained showed that MDR1
rs1045642 was associated with the increased risk of
CRC in the population of Central Russia.
The ATP-binding cassette transporter B1 (ABCB1,
P-glycoprotein, multidrug resistance protein 1 (MDR1))
functions as unidirectional transporter that mediates
the outflux of a wide range of endogenous and xeno-
biotic compounds, thereby protecting cells against
potentially toxic substances. ABCB1 has unusually
wide multispecificity for numerous substrates, most of
which are hydrophobic [23]. The localization of P-gp
in the apical membrane of enterocytes points to its role
in the eff lux of possibly toxic xenobiotics out of the
intestine [24]. It is noteworthy that the highest aggre-
gation of P-gp was observed in distal part of digestive
tract, especially in the colorectal region [25]. In addi-
tion, association between the ABCB1 gene and the
Wnt/β-catenin signaling cascade was revealed; the last
one is the most common dysfunction in rare heredi-
tary forms of CRC [26]. Moreover, in vitro studies
demonstrated that ABCB1 expression was observed in
cells with P53 mutations (P53 mutations are found in
50% of CRC cases) [27].
Considering that the main function of the ABCB1
product is the eff lux of a number of toxic xenobiotic
compounds out of cells, it can be suggested that altered
P-gp function can lead to the development of intracel-
lular toxic and chemical stress and, thereby, increase
the risk of DNA damage by the products of incomplete
xenobiotic metabolism (potential carcinogens), medi-
ating the susceptibility of colon cells to tumor transfor-
mation.
In addition, it should be noted that the present
study showed sex-specific effects in association of
ABCB1 C3435T polymorphism with the risk of CRC.
In most countries of the world, the morbidity and
mortality rates from CRC are considerably higher
among males than among females [28]. On the other
hand, several studies reported higher survival rates in
females with CRC compared to males [29, 30]. First,
gender can reflect different levels of environmental
factors associated with occupational exposure, diet, or
lifestyle. Second, sex hormones can also affect the
expression of genes associated with the development
of this disease. It should be noted that steroid hor-
mones, such as progesterone, are able to modulate
P-gp expression in some tissues, as evidenced by stud-
ies in mice [31]. On the other hand, SNPs can alter
ABCB1 expression, affecting the regulatory sequences
that are targeted by steroid hormones, or can alter the
ability of ABCB1 to metabolize specific substances,
the consumption of which may be sex-dependent.
This hypothesis is consistent with the results of
Nakamura et al. [32], who suggested that serum corti-
sol and aldosterone levels in females could depend on
ABCB1 rs1045642 polymorphism [32].
Thus, the results of the present study demonstrated
that MDR1 C3435T polymorphism was associated
with an increased risk of CRC in the population from
Central Russia, exclusively in females. Further studies
on a larger sample size, as well as replication studies,
are required to confirm the role of MDR1 C3435T
(rs1045642) in the pathogenesis of colorectal cancer,
especially in terms of gene-gene and gene–environ-
ment interactions.
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